Amoxil®
Amoxicillin · oral capsule
Antibiotic
Approved uses
Infections of the ear, nose and throat, genitourinary tract, skin and skin structure, and lower respiratory tract due to susceptible beta-lactamase-negative isolates; H. pylori infection and duodenal ulcer disease, with clarithromycin plus lansoprazole, or with lansoprazole in patients allergic or intolerant to clarithromycin or with known or suspected clarithromycin resistance
Adults and patients 40 kg or more: 500 mg every 12 hours or 250 mg every 8 hours, or 875 mg every 12 hours or 500 mg every 8 hours for severe and lower respiratory infection. Pediatric patients older than 3 months under 40 kg: 20 to 45 mg/kg/day divided every 8 to 12 hours. H. pylori triple therapy: 1 g twice daily with clarithromycin 500 mg and lansoprazole 30 mg for 14 days. Dual therapy: 1 g three times daily with lansoprazole 30 mg for 14 days.
OFF-LABELNot in the FDA label for this product
Preseptal (periorbital) cellulitis
Label regimen for skin and skin structure infection: adults and patients over 40 kg 500 mg every 12 hours or 250 mg every 8 hours, or 875 mg every 12 hours or 500 mg every 8 hours if severe; pediatric patients 3 months and older under 40 kg 20 to 45 mg/kg/day divided every 8 to 12 hours.
Narrative review · no trials
A narrative review of pediatric preseptal and orbital cellulitis lists amoxicillin among the antibacterials often used, notes significant variation in agent selection, supports transition from IV to oral therapy once clinical and laboratory improvement is clear, and reports total durations trending toward about 2 weeks. It offers practice pattern and antimicrobial stewardship guidance, not comparative efficacy data. Coverage is the practical limit: the label confines the skin and skin structure indication to beta-lactamase negative Streptococcus spp., Staphylococcus spp., and E. coli, so beta-lactamase producing staphylococci fall outside it.
Contraindications
History of a serious hypersensitivity reaction such as anaphylaxis or Stevens-Johnson syndrome to amoxicillin or to other beta-lactams, including penicillins and cephalosporins.
Capsules 250 mg (bottles of 100, 500) and 500 mg (60, 100, 500); for oral suspension 125 mg/5 mL and 250 mg/5 mL (80, 100, 150 mL)
Penicillin-class antibacterial and analog of ampicillin; bactericidal against susceptible bacteria during the stage of active multiplication by inhibiting cell wall biosynthesis. Resistance is mediated primarily by beta-lactamases that cleave the beta-lactam ring and render it inactive, and the label limits the ear, nose, throat, genitourinary, skin and lower respiratory indications to beta-lactamase-negative isolates.
Warnings & Precautions
- Anaphylactic reactions: Serious and occasionally fatal reactions have been reported on penicillin therapy, more often parenterally but also on oral penicillins. Risk is higher with a history of penicillin hypersensitivity and/or sensitivity to multiple allergens, and severe cephalosporin reactions have been reported with penicillin hypersensitivity. Ask about prior reactions to penicillins, cephalosporins, or other allergens, and discontinue if an allergic reaction occurs.
- Drug-induced enterocolitis syndrome (DIES): Non-IgE mediated hypersensitivity reaction with protracted vomiting 1 to 4 hours after ingestion in the absence of skin or respiratory symptoms, with most cases in pediatric patients younger than 18 years; may be associated with pallor, lethargy, hypotension, shock, diarrhea within 24 hours, and leukocytosis with neutrophilia. If DIES occurs, discontinue and institute appropriate therapy.
- Clostridium difficile-associated diarrhea: Reported with nearly all antibacterials and may range from mild diarrhea to fatal colitis; hypertoxin-producing strains increase morbidity and mortality, and infections can be refractory to antimicrobial therapy and may require colectomy. Consider CDAD in all patients with diarrhea after antibacterial use; take a careful history, since it has been reported over 2 months later. If suspected or confirmed, antibiotics not directed against C. difficile may need stopping.
- Development of drug-resistant bacteria: Prescribing in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit and increases the risk of drug-resistant bacteria.
- Skin rash in mononucleosis: A high percentage of patients with mononucleosis who receive it develop an erythematous rash; do not administer in mononucleosis.
- Increased incidence of rash: Concurrent allopurinol increases the incidence of rash compared with amoxicillin alone.
- Abnormal prolongation of prothrombin time: Increased INR has been reported with oral anticoagulants; monitor appropriately, and anticoagulant dose adjustments may be necessary.
- Reduced efficacy of oral contraceptives: Amoxicillin may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen and progesterone contraceptives.
Common Side Effects
The most common adverse reactions (more than 1%) were diarrhea, rash, vomiting, and nausea. With H. pylori triple therapy the most frequent were diarrhea (7%), headache (6%), and taste perversion (5%); with dual therapy, diarrhea (8%) and headache (7%). Events identified during postmarketing use of penicillins, for which estimates of frequency cannot be made, include anaphylaxis, serum sickness-like reactions, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, urticaria, mucocutaneous candidiasis, drug-induced enterocolitis syndrome, and hemorrhagic/pseudomembranous colitis. A moderate rise in AST and/or ALT of unknown significance, cholestatic jaundice, crystalluria, anemia, thrombocytopenia, agranulocytosis, convulsions, and tooth discoloration have also been reported.
Pregnancy: Category B. Reproduction studies in mice and rats at up to 2000 mg/kg (3 and 6 times the 3 g human dose by body surface area) showed no evidence of fetal harm, but there are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, use during pregnancy only if clearly needed.
Lactation: Penicillins are excreted in human milk and use by a nursing mother may sensitize the infant; exercise caution.
Elimination may be delayed in neonates and young infants because of incompletely developed renal function; modify dosing at 12 weeks or younger (3 months or younger).